Evidence map›Paper›PMID 41596530›Full record

ReviewInternational journal of molecular sciences2026

FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer's Disease: Where Are We Now?

Martin Higgins, Veronica Wasef, Andrea Kwakowsky

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Martin HigginsPharmacology and Therapeutics, School of Pharmacy and Medical Sciences, Institute for Health Discovery and Innovation, Institute for Clinical Trials, Galway Neuroscience Centre, University of Galway, H91 TK33 Galway, Ireland.
Veronica WasefPharmacology and Therapeutics, School of Pharmacy and Medical Sciences, Institute for Health Discovery and Innovation, Institute for Clinical Trials, Galway Neuroscience Centre, University of Galway, H91 TK33 Galway, Ireland.
Andrea KwakowskyPharmacology and Therapeutics, School of Pharmacy and Medical Sciences, Institute for Health Discovery and Innovation, Institute for Clinical Trials, Galway Neuroscience Centre, University of Galway, H91 TK33 Galway, Ireland.ORCID 0000-0002-3801-4956

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder marked by decreased amyloid-beta (Aβ) clearance, enhanced Aβ aggregation, an increased risk of amyloid-related imaging abnormalities (ARIA), and blood-brain barrier (BBB) dysfunction. The

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesImmunization, PassiveAnimalsAntibodies, MonoclonalApolipoprotein E4BiomarkersBlood-Brain BarrierDrug ApprovalHumansUnited StatesUnited States Food and Drug AdministrationAmyloid beta-PeptidesAntibodies, MonoclonalApolipoprotein E4BiomarkersAlzheimer’s diseaseAPOE4ARIAAβmAb

Identifiers

PMID41596530
PMCPMC12841311

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.